Mineralys (NASDAQ: MLYS) holder files to sell 6,348 shares of common stock

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. shareholder David Rodman has filed a notice to sell 6,348 shares of common stock. The shares are to be sold on NASDAQ through Merrill Lynch at an aggregate market value of $205,142.99, with the sale expected around 01/12/2026. The issuer reports 79,139,956 common shares outstanding.

The 6,348 shares were acquired on 01/12/2026 through the exercise of employee stock options in a broker-assisted cashless exercise from Mineralys Therapeutics, Inc. In the past three months, David Rodman has also sold Mineralys common stock, including 10,369 shares on 10/15/2025 for $445,982.61, 70,037 shares on 01/02/2026 for $2,511,919.03, and 192,715 shares on 01/05/2026 for $6,749,100.06.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	6348	205142.99	79139956	01/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/12/2026	Exercise of employee stock options	Mineralys Therapeutics, Inc.			6348	01/12/2026	Broker assisted cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	10/15/2025	10369	445982.61
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/05/2026	192715	6749100.06
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/02/2026	70037	2511919.03
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common stock	01/09/2026	2170	72195.90

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Mineralys (MLYS) Form 144 filing disclose?

The filing discloses that shareholder David Rodman plans to sell 6,348 shares of Mineralys Therapeutics, Inc. common stock on NASDAQ through Merrill Lynch, with an aggregate market value of $205,142.99.

How were the 6,348 Mineralys (MLYS) shares being sold acquired?

The 6,348 common shares were acquired on 01/12/2026 via an exercise of employee stock options from Mineralys Therapeutics, Inc., using a broker-assisted cashless exercise structure.

How many Mineralys (MLYS) shares are outstanding according to this notice?

The notice states that 79,139,956 shares of Mineralys Therapeutics, Inc. common stock were outstanding at the time referenced in the filing.

Which broker and exchange are involved in the planned Mineralys (MLYS) share sale?

The planned sale of 6,348 Mineralys common shares will be executed through Merrill Lynch, with the shares traded on the NASDAQ exchange.

What recent Mineralys (MLYS) stock sales has David Rodman reported?

Over the past three months, David Rodman has reported sales of Mineralys common stock, including 10,369 shares on 10/15/2025 for $445,982.61, 70,037 shares on 01/02/2026 for $2,511,919.03, and 192,715 shares on 01/05/2026 for $6,749,100.06.

What representation does the seller make in this Mineralys (MLYS) Form 144?

The person for whose account the securities are to be sold represents by signing that they do not know any material adverse information about Mineralys Therapeutics, Inc. that has not been publicly disclosed.